Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that.
The question about c-cell question that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
If someone has run c-cell question properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
On the "does it stop working" question: tolerance in the pharmacological sense is not what the withdrawal trials show. What they show is that the effect persists while treatment continues and reverses when it stops, which is a different finding with different implications.
I had written a reply contradicting post #2 and deleted it. Here is what survived.
The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.
This follows post #4 rather than contradicting it.
Two people in this thread mean different things by c-cell question and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
The version of c-cell question that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
I have written this out at length because the short version keeps being misread.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
Post #6 and I disagree about the size of the effect, not about the direction.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Where I part company with post #9, and it is a narrow parting.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
Worth reading the earlier posts in this thread before acting on mine.
I keep a log for c-cell question specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Quietly grateful for the plain phrasing. Not every thread gets that.
Adding the measurement that post #12 says would settle it.
Before the thread moves on from c-cell question — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
I had written a reply contradicting post #14 and deleted it. Here is what survived.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
I am not the right person to answer the follow-up to this.
Confirming post #14 from a second method, which matters more than confirming it from a second person.
Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.
That is the version I use. It may not be the version that is correct.
Small correction to my own earlier position on c-cell question. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Taking post #17 at face value and following it one step further.
The question underneath c-cell question is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
One case, stated as one case.
Where I part company with post #20, and it is a narrow parting.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Adding the measurement that post #22 says would settle it.
Nobody has said the unglamorous part of c-cell question yet, so: most of the variation is explained by things that are boring to write about and easy to check.
The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.
One more caveat and then I will stop qualifying: the sample selected itself.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
I would want the raw data before agreeing with my own summary of it.
Picking up post #26: that is the part I would want checked first.
C-cell question is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
On post #24 — agreed on the reasoning, with one qualification.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
Adding the boring version of c-cell question, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
The confident answers on c-cell question and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.